article · Biochemistry Letters
Background: Bee venom is a medicine that is frequently used Because of the bioactive compounds and its pharmacological properties. Necrosis, cytotoxicity, impacts on proliferation, induction of apoptosis, and a decrease in the growth of different cancer cell types are only a few of the effects of B.V. that have recently been observed. Aim: This research aims to verify the effectiveness of bee venom in the prevention and treatment of liver cancer. Method: Fifty male albino mice, weighing around 20–25 g, were residing in the animal house of the Faculty of medicin, Zagazig University. mice used in the experiment were separated into 5 groups, as follows: Group (1) control group: normal mice. Group (2) positive group: HCC induction was performed utilizing carbon tetra chloride (CCL4) 2ml/kg was given IP twice weekly for two months to develop HCC. Group (3) Treatment group: mice treated with Bee venom (0.1mg/kg/orally) for 45 day after HCC induction. Group (4) protective group: mice took Bee venom (0.1 mg/kg /orally) daily for 45day then took carbon tetra chloride for 2 months. Group (5) Cisplatin group: mice administered cisplatin (1.5 mg/kg /i.p) after induction of HCC. Result: After treatment was over, the animals were sacrificed with an injection of urethane (1g/kg body weight). All the animals in the various experimental groups received their blood and liver tissues. These activities were assessed by investigating the liver enzymes ALT, AST, Alb and immunohistochemical marker AFP. Increases in ALT, AST, ALP and immunohistochemical marker AFP were observed in mice who received CCl4 only, in contrast to mice that took Bee venom after CCl4 administration and protective group with statistically significant value p<0.05. Conclusion: The current study indicate that the Bee venom may assist in the therapy and improving the recovery of the HCC. due to its anti-inflammatory, antioxidant and anticancer effects.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/blj.2024.340261
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.